Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a Healthcare company (Biotechnology) with a market capitalization of $8.9B. The Maz Rating grades it against the other companies in its sector.
Spyre Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $93.81, Spyre Therapeutics, Inc. trades at 98.3x sales and 7.9x book value. Over the last twelve months it generated about $91M of revenue and a net loss of $261M. It runs a gross margin of 50.0%, an operating margin of -276.5% and a net margin of -291.6%. It shows return on equity of -29.8%, return on invested capital of -23.6% and a free cash flow yield of -2.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 27.40. Over the past 52 weeks the share price ranged from $23.01 to $110.64, with a beta of 3.23.
Spyre Therapeutics, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 12 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Spyre Therapeutics, Inc. (SYRE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 13.0% / 30% · Interest income / Revenue 1062500000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 13.0% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 1062500000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 13.0% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 1062500000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 97.4% / 33.33% · Receivables / Avg Assets (4Q) 0.12% / 33.33% · Interest income / Revenue 1062500000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 97.5% / 33.33% · (Cash+Recv) / Total Assets 97.5% / 33.33% · Interest income / Revenue 1062500000.0% / 5% | Fail |
No. As of September 2026, Spyre Therapeutics, Inc. (SYRE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Spyre Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 1062500000.0% of each dividend: Spyre Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.